We describe the pharmacological properties of a novel spermine-cholesterol adduct, MSI 1436 (3b-N-1(spermine)-7a, 24R-dihydroxy-5a-cholestane 24-sulfate), which causes reversible suppression of food and¯uid intake in mammals resulting in profound weight loss, not associated with other signs or symptoms of illness, and which exhibits antidiabetic properties in genetically obese mice. METHODS: Wild-type rodents and strains with genetic obesity were studied. Effects on food and¯uid intake, body weight and composition were examined along with pharmacological and toxicological parameters. RESULTS: MSI-1436 induces profound inhibition of food and¯uid intake in rats and mice, resulting in signi®cant weight loss. MSI-1436 is active when introduced directly into the third ventricle of the rat, suggesting the compound acts on central targets. Pair-feeding studies suggest that MSI-1436 causes weight loss by suppressing food intake. Fluid intake is also profoundly reduced but animals remain normally hydrated and defend both water and electrolyte balance from parenteral administration. MSI-1436 is active in obaob, dbadb, agouti and MC4 receptor knockout mice. MSI-1436 has been administered to obaob mice over a 4 month period via a regimen that safely controls body weight, glucose homeostasis and serum cholesterol levels. Following MSI-1436 treatment, dbadb mice preferentially mobilize adipose tissue and hyperglycemia is corrected. CONCLUSION: A naturally occurring spermine metabolite of cholesterol, isolated from the dog®sh shark, Squalus acanthias, has been identi®ed that induces profound reduction in food and¯uid intake in rodents in a setting where thirst is preserved and¯uid and electrolyte homeostasis appears to be functioning normally. MSI-1436 probably acts on a central target involving neural circuits that lie downstream from the leptin and the MC4 receptors. Although long-term administration can be accomplished safely in mice, the utility of this compound as a potential human therapeutic awaits an analysis of its pharmacological properties in man.
Introduction
In this report we describe the pharmacological properties of MSI-1436 (Figure 1 ), a naturally occurring spermine metabolite of cholesterol of vertebrate origin that potently suppresses food intake following systemic or central administration and that reverses the diabetic phenotype in genetically obese mice.
In 1993, we reported the discovery of the antibiotic squalamine, a sulfated oxysterol adduct of spermidine from tissues of the dog®sh shark, Squalus acanthias. 1 While extracting squalamine from dog®sh liver, we isolated several less abundant, structurally related aminosterols. 2 One of these, MSI-1436, inhibited replication of HIV in human mononuclear cells. 3 Additional studies on various cell types indicated that MSI-1436 affected chloride, calcium and proton¯uxes. 4, 5 When studied in animals, however, MSI-1436 caused unexpected weight loss in rodents, dogs and monkeys. This report describes its effects on rodents.
Materials and methods
Aminosterols MSI-1436 and MSI-1701 were synthesized by coupling spermine to the (5a, 7a, 24R)-3-keto-7-hydroxycholestan-24-ol sulfate steroid intermediate as described. 2, 6, 7 MSI-1814 was prepared by the same procedure as MSI-1436 but by using the opposite chiral catalyst during reduction of C-24 (SMeCBS from Callery Chemical Co., Pittsburgh, PA). The synthesis of the 7-b isomer, MSI-1673 and other compounds will be described elsewhere (Kinney et al, manuscript in preparation).
Animal studies
All procedures were performed in compliance with institutional animal care policy. General methods used in animal studies, unless amended in the ®gure legends, were as follows: experiments were performed using age-matched (4 ± 5 weeks old) sex-matched litters of mice (Jackson Laboratories) or rats (Sprague ± Dawley, Taconic Farms, Germantown, NY) provided with food and water ad libitum. Mice corresponding to a single experimental cohort were housed together in a single cage; rats were housed in individual cages. Animals were used 1 week after arrival. Lights were on from 06:00 to 18:00 and room temperature was kept at 21 AE 2 C. Daily (or as otherwise noted), at 08:00 ± 10:00 animals were weighed, food and water replaced, and drug dosing was conducted; food consumption of mice over the previous 24 h was determined by weighing remaining food in each cage and averaged for the number of mice per cage. For rats, consumption per animal was measured and the mean of each cohort presented.
Pharmacokinetics MSI-1436 was administered over 10 min by tail vein to rats as a 1 mgaml solution in water. Water was used as the vehicle in all experiments with mice, unless otherwise noted. Blood samples were drawn by orbital puncture at the times noted and collected in EDTA anticoagulant. Each sample of blood was acidi®ed with 0.1-volume 1 N HCl; the supernatant was then collected following centrifugation, applied to a C 18 Sep Pak (Waters) and MSI-1436 was eluted with 60% acetonitrile, 0.1% tri¯uoracetic acid and dried under vacuum. Samples were analyzed on a Hewlet Packard API Electrospray LC-MS system and the amounts of MSI-1436 present (corresponding to a positive ion of 685 atomic mass units) estimated by comparison with standards of known weight. Recovery was adjusted by normalizing to the recovery of a known amount of squalamine introduced into each blood sample prior to the extraction.
Results
Rats on an ad libitum diet given a single dose of MSI-1436 (10 mgakg, i.v.) exhibited profound weight loss over time with eventual recovery over several days (Figure 2A ) associated with a reduction in both food and water intake within the ®rst 24 h ( Figure 2B and C). Urine output fell ( Figure 2D ), but creatinine clearance, an index of glomerular ®ltration rate, changed minimally ( Figure 2E ), suggesting that reduced urinary output resulted from lower¯uid intake, not from impaired renal function.
Toxicological studies were conducted in rats receiving doses of MSI-1436 that produced maximum weight loss in the 12 ± 28% range. At all times, including the period prior to maximal weight loss, during the phase of recovery, as well as during the nadir in weight, animals appeared healthy by physical examination; clinical chemistries and hematological indices were within normal limits, and gross and microscopic examination of tissues revealed no evidence of pathology.
The pharmacokinetic behavior of MSI-1436 in the vascular compartment was determined in the rat. When administered as an intravenous (i.v.) bolus of 1.9 mgakg, MSI-1436 reaches a peak plasma concentration of about 14 mgaml and exhibits a complex multiphasic pattern, with an estimated half-life in the blood stream of 1 week (data not shown). Although a slight effect on food intake can be detected as early as 2 h following i.v. administration, the magnitude of depression in food intake increases progressively over several days, demonstrating that the pharmacological response to MSI-1436 does not correlate with its blood levels. Comparable pharmacokinetic data have been obtained in the mouse. Following administration to the mouse, MSI-1436 distributes into many tissues and is observed to accumulate in the liver over several days, while it gradually decreases in concentration in most other organs (Table 1) .
To ascertain whether MSI-1436 acts through peripheral or central pathways, the compound, or a structurally related, inactive analog, MSI-1459 (3b-spermine, 5a, cholenic acid methyl ester), was introduced directly into the third ventricle of cannulated rats. Prolonged weight loss, followed by recovery, was observed after administration of MSI-1436 (but not the inactive aminosterol) at a dose about 1a300th the amount required systemically to produce a comparable effect (eg 0.03 vs 10 mgakg), suggesting central activity ( Figure 3A ). Blood samples were drawn in the morning for creatinine determination, and were used to estimate clearance based on the total urinary creatinine collected during the preceding 24 h.
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To con®rm that MSI-1436-induced weight loss corresponds to reduced food and¯uid intake, we conducted a pair-feeding experiment in mice treated with either MSI-1436 or sterile water ( Figure 3B ). The untreated group ( Figure 3B , triangles) was fed the exact amount of food ingested by the treated cohort ( Figure 3B , squares) during the preceding 24 h period. Weight loss in the two groups was similar in magnitude and kinetics, suggesting that food and uid intake alone adequately accounted for the change. What would occur if an MSI-1436 treated animal were forced to consume¯uid? A cohort of MSI-1436 treated mice were weighed daily and the difference in their weight from an untreated control (Figure 4 , diamonds) replaced fully by a daily intraperitoneal administration of an isotonic electrolyte solution. Immediately following¯uid replacement, animals were weighed (Figure 4, circles) , and con®rmed to have been acutely supplemented with¯uid to the body weight of untreated controls. However, 24 h later, MSI-1436 treated mice receiving full parenteral compensation in isotonic uid ( Figure 4 , squares) were identical in weight to those MSI-1436 treated animals offered water ad libitum ( Figure 4 , triangles); the weight curves of both¯uid supplemented and unsupplemented cohorts were almost identical ( Figure 4 , squares and triangles). Serum chemistries of treatment and control groups representing hydration status were indistinguishable. On day nine an analog of antidiuretic hormone, DDAVP was administered (Figure 4 , squares). Animals responded with a robust retention of¯uid characterized by dilutional hyponatremia and an increase in body weight, demonstrating that the kidneys of these treated animals could retain water given a suitable physiological stimulus. This experiment suggests that animals treated with MSI-1436 have established a new physiologically appropriate`set' point with respect to¯uid intake (and total body water), which appears to be defended through functional homeostatic mechanisms.
Leptin and melanocortin stimulating hormone are wellcharacterized modulators of food intake. 8 ± 10 To evaluate whether MSI-1436 in¯uences feeding behavior through these neurohumoral pathways, MSI-1436 was administered to obaob (leptin de®cient) and dbadb (leptin receptor de®-cient) mice (data not shown). While the dbadb individuals consistently responded to MSI-1436 with a longer delay than observed in either wild-type animals or obaob individuals, weight loss in these genetically obese strains, as well as in agouti and MC-4 receptor knockout mice was comparable to that in wild-type controls, indicating that the MSI-1436 appetite suppressant effect is independent of leptin or melanocortin signaling central pathways.
To determine the long-term effects of MSI-1436 on the metabolic status of genetically obese mice, obaob animals were treated once weekly for 4 months ( Figure 5 ). MSI-1436 produces a dose-dependent reduction in weight gain. Animals receiving 10 or 20 mgakgaweek lose excessive weight and grow emaciated and moribund within several weeks ( Figure 5A ). However, safely managed weight control (ie no deaths) was possible over a 4 month period using an intermittent dosing regimen ( Figure 5A, 3.1 mgakgaweek cohort) . Obaob mice eventually develop diabetes, possibly because of fat accumulation within pancreatic islet cells. 11, 12 Animals were evaluated about 40 days after treatment ceased (day 63). Mice receiving 3.1 mgakgaweek were within 10% above their starting weight, while untreated controls had gained 70%. An oral glucose tolerance test revealed a normal metabolic response in the MSI-1436 treated group, in contrast to the diabetic pattern observed both in the vehicle-treated cohort ( Figure 5B ) and the MSI-1436 treated cohort prior to the initiation of MSI-1436 dosing (data not shown). At 120 days, after dosing had resumed, serum cholesterol was in the normal range in animals with controlled weight gain (1.0 and 3.1 mgakgaweek), regardless of their absolute weight ( Figure 5C ).
To explore the relationship between the chemical structure of MSI-1436 and its pharmacological activity, a series of analogs were synthesized and evaluated in mice ( Figure 6 ). Analogs that differ from MSI-1436 at a single stereocenter, such as MSI-1701 (the polyamine at C-3), MSI-1673 (the OH at C-7), or MSI-1777 (the methyl at C-20) exhibit reduced activity. The naturally occurring aminosterol, squalamine (MSI-1256), identical to MSI-1436 except for a difference in the polyamine, is inactive, highlighting the importance of a precise polyamine structure (not shown). This can be further Mice (20 ± 25 g) were administered MSI-1436 (10 mgakg). Animals (two each) were euthanized at times noted. Tissues were harvested, weighed and MSI-1436 extracted and puri®ed by HPLC essentially as described perviously. 
demonstrated by the analog MSI-1750, identical to MSI-1436, but differing by the substitution of the two central amino groups of the spermine moiety with oxygens. Addition of a propyl group on the primary amine of the MSI-1436 molecule also reduces activity (MSI-1888), as does the addition of a CH 2 OH group on C-24 (MSI-1839). The presence of the sulfate on the C-24 hydroxyl moiety is required for activity (MSI-1521) (not shown). However, chirality of the C-24 hydroxyl itself appears to be relatively unimportant (MSI-1814). These studies suggest that MSI-1436 affects weight loss through a speci®c pathway, rather than as a consequence of a`nonspeci®c' side-effect of this chemical class of substance. What endogenous energy sources do MSI-1436 treated animals utilize during periods of anorexia? We measured the body composition of dbadb mice treated with MSI-1436 ( Table 2) . Over a 20-day period the weight of untreated homozygotes increased from about 28 to 39 g. Treated MSI-1436 effects on weight are principally due to decreased food intake. Three groups (eight animalsagroup) of male CD-1 mice (4 ± 5 weeks old) were fed an enriched food consisting of cubes of 0.4% agar containing a nutrient source (1.9 kcalag, comprised of 3% (wav) hydrolyzed protein, 3.9% (wav) lipid and 18% (wav) glucose). On this diet animals gained weight. One cohort was dosed with MSI-1436 (10 mgakgaday, s.c.) on days 0, 1, 2 and 3, while the other two received sterile water. Food intake of the MSI-1436 treated animals was measured and the pair-fed cohort provided with the identical amount of food on the following day. All food given to the pair-fed group was consumed. Water was provided ad libitum. (Diamonds) untreated, fed ad libitum; (squares) MSI-1436 treated, fed ad libitum; (triangles) untreated, pair-fed.
Suppression of food and¯uid intake by an aminosterol M Zasloff et al animals dropped from about 31 to 20 g; their body composition was signi®cantly lower in fat and higher in lean mass than the untreated dbadb cohort. However, the treated dbadb animals still retained a higher percentage of body fat than phenotypically normal (but untreated) dba heterozygotes of about the same age and weight. In terms of the energy stores mobilized during reduced food intake the effects of MSI-1436 resemble those of starvation. 12 Note that the severe hyperglycemia of the dbadb homozygote was corrected, reduced from 465.0 to 53.5 mgadl ( Table 2 ).
Discussion
This report shows that an unusual spermine-coupled cholesterol metabolite present in the dog®sh shark, an animal that lacks adipose tissue, profoundly reduces food and¯uid intake in a mammal, depleting stored fat and ameliorating the diabetic phenotype in genetically obese mice. Doses of MSI-1436 can be administered which induce weight loss in a setting where animals appear clinically healthy, display normal clinical chemistries, normal gross and microscopic status of major organs, and unremarkable neurological and social behavior. In addition, minute amounts of MSI-1436 can induce anorexia when introduced directly into the brain of the rodent compared to the dose required to achieve a comparable effect by parenteral administration. Our data suggest that MSI-1436 in¯uences feeding and drinking behavior by acting on a structure in the brain.
We have shown that MSI-1436 treated animals appear to reduce both food and¯uid intake as if they were resetting their needs for that of a smaller organism. Attempts at parenteral rehydration demonstrate that, although animals are in net negative caloric balance, they remain adequately hydrated. Thus, the MSI-1436 treated animals ingest amounts of¯uid commensurate with their reduced size and food intake.
To try to narrow down the central circuits that MSI-1436 affects we have considered this compound's capacity to suppress food intake while preserving water and electrolyte balance, 13 implicating, as potential targets, circuits involved principally in feeding. Amongst the best-studied circuits regulating food intake are those arising within the hypothalamus, projecting from the arcuate nucleus (ARC). From this site emanate neurons that express NPY (which stimulates eating) and aMSH (which inhibits eating) and project into the lateral hypothalamic area (LHA), the dorsomedial nucleus (DMN) and the paraventricular nucleus (PVN). Leptin is believed to inhibit NPY rich neurons of the ARC and stimulate aMSH expressing neurons, resulting in suppression of feeding. 8, 14, 15 Since MSI-1436 acts in animals lacking either leptin, the leptin receptor or the MC4 receptor, its activity must be expressed at sites downstream from the site of action of both leptin and aMSH.
The structural requirements that characterize the anorexic property of the MSI-1436 molecule are strikingly speci®c. These structural constraints can be explained in several usual ways. For example, MSI-1436 might be acting on a highly speci®c`receptor'; or, alternatively, the stringent structural constraints on its pharmacological activity could re¯ect the structural constraints of putative metabolic enzymes that transform MSI-1436 into an as yet uncharacterized biologically active compound. Suppression of food and¯uid intake by an aminosterol M Zasloff et al MSI-1436, a naturally occurring cholesterol derivative present in the tissues of the dog®sh shark, appears to represent a new class of pharmacologically active substances. Through careful management of the dosing regimen of this compound it has been possible to control the food intake, weight gain and glucose homeostasis of genetically obese mice offered ad libitum access to food and water, which otherwise grow morbidly obese and develop diabetes. A similar bene®t is afforded by caloric restriction in humans with type 2 diabetes. 16 The pharmacological properties of Suppression of food and¯uid intake by an aminosterol M Zasloff et al MSI-1436 in humans will ultimately determine its potential as a therapeutic for the control of body weight in man.
